Cargando…

Oocyte-Secreted Serum Biomarkers GDF9 and BMP15 in Women with Endometriosis

Oocyte-secreted growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) are critical paracrine regulators of female fertility. Recent studies demonstrated that serum concentrations are associated with the number of oocytes retrieved during IVF, and therefore potential clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shamsa, Aiat, Gilchrist, Robert B., Robertson, David M., Rodgers, Rachael J., Donoghoe, Mark W., Ledger, William L., Abbott, Jason A., Riepsamen, Angelique H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160143/
https://www.ncbi.nlm.nih.gov/pubmed/36380138
http://dx.doi.org/10.1007/s43032-022-01107-6
_version_ 1785037224737243136
author Shamsa, Aiat
Gilchrist, Robert B.
Robertson, David M.
Rodgers, Rachael J.
Donoghoe, Mark W.
Ledger, William L.
Abbott, Jason A.
Riepsamen, Angelique H.
author_facet Shamsa, Aiat
Gilchrist, Robert B.
Robertson, David M.
Rodgers, Rachael J.
Donoghoe, Mark W.
Ledger, William L.
Abbott, Jason A.
Riepsamen, Angelique H.
author_sort Shamsa, Aiat
collection PubMed
description Oocyte-secreted growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) are critical paracrine regulators of female fertility. Recent studies demonstrated that serum concentrations are associated with the number of oocytes retrieved during IVF, and therefore potential clinical use as biomarkers. However, it is unknown if the presence of endometriosis affects serum GDF9 or BMP15. An exploratory case–control study was prospectively performed on 60 women who underwent laparoscopy between April 2017 and August 2018 at two hospitals. GDF9 and BMP15 were measured by validated immunoassays in pre-operative serum samples. Data were analysed relative to laparoscopic assessment of endometriosis and staging. There were 35 women with confirmed laparoscopic diagnosis of endometriosis and 25 controls with no evidence of endometriosis at laparoscopy. GDF9 was detectable in 40% of controls and 48% of cases. There was no difference in median GDF9 concentrations between controls (20.0 pg/ml, range 20.0–2504 pg/ml) and cases (20.0 pg/ml, range 20.0–2963 pg/ml). BMP15 was detectable in 48% of controls and 58% of cases, with no difference in median concentrations between controls (26.5 pg/ml, range 24.0–1499 pg/ml) and cases (24.0 pg/ml, range 24.0–796 pg/ml). Furthermore, there were no significant differences in the proportion of detectable samples or concentrations of GDF9 or BMP15 with differing severities of endometriosis. In conclusion, serum concentrations of oocyte-secreted factors, GDF9 and BMP15 did not differ between control patients and patients with endometriosis. For clinical application in reproductive medicine, GDF9 and BMP15 serum biomarker quantitation is unlikely to be aberrant in the presence of endometriosis.
format Online
Article
Text
id pubmed-10160143
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-101601432023-05-06 Oocyte-Secreted Serum Biomarkers GDF9 and BMP15 in Women with Endometriosis Shamsa, Aiat Gilchrist, Robert B. Robertson, David M. Rodgers, Rachael J. Donoghoe, Mark W. Ledger, William L. Abbott, Jason A. Riepsamen, Angelique H. Reprod Sci Reproductive Biology: Original Article Oocyte-secreted growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) are critical paracrine regulators of female fertility. Recent studies demonstrated that serum concentrations are associated with the number of oocytes retrieved during IVF, and therefore potential clinical use as biomarkers. However, it is unknown if the presence of endometriosis affects serum GDF9 or BMP15. An exploratory case–control study was prospectively performed on 60 women who underwent laparoscopy between April 2017 and August 2018 at two hospitals. GDF9 and BMP15 were measured by validated immunoassays in pre-operative serum samples. Data were analysed relative to laparoscopic assessment of endometriosis and staging. There were 35 women with confirmed laparoscopic diagnosis of endometriosis and 25 controls with no evidence of endometriosis at laparoscopy. GDF9 was detectable in 40% of controls and 48% of cases. There was no difference in median GDF9 concentrations between controls (20.0 pg/ml, range 20.0–2504 pg/ml) and cases (20.0 pg/ml, range 20.0–2963 pg/ml). BMP15 was detectable in 48% of controls and 58% of cases, with no difference in median concentrations between controls (26.5 pg/ml, range 24.0–1499 pg/ml) and cases (24.0 pg/ml, range 24.0–796 pg/ml). Furthermore, there were no significant differences in the proportion of detectable samples or concentrations of GDF9 or BMP15 with differing severities of endometriosis. In conclusion, serum concentrations of oocyte-secreted factors, GDF9 and BMP15 did not differ between control patients and patients with endometriosis. For clinical application in reproductive medicine, GDF9 and BMP15 serum biomarker quantitation is unlikely to be aberrant in the presence of endometriosis. Springer International Publishing 2022-11-15 /pmc/articles/PMC10160143/ /pubmed/36380138 http://dx.doi.org/10.1007/s43032-022-01107-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Reproductive Biology: Original Article
Shamsa, Aiat
Gilchrist, Robert B.
Robertson, David M.
Rodgers, Rachael J.
Donoghoe, Mark W.
Ledger, William L.
Abbott, Jason A.
Riepsamen, Angelique H.
Oocyte-Secreted Serum Biomarkers GDF9 and BMP15 in Women with Endometriosis
title Oocyte-Secreted Serum Biomarkers GDF9 and BMP15 in Women with Endometriosis
title_full Oocyte-Secreted Serum Biomarkers GDF9 and BMP15 in Women with Endometriosis
title_fullStr Oocyte-Secreted Serum Biomarkers GDF9 and BMP15 in Women with Endometriosis
title_full_unstemmed Oocyte-Secreted Serum Biomarkers GDF9 and BMP15 in Women with Endometriosis
title_short Oocyte-Secreted Serum Biomarkers GDF9 and BMP15 in Women with Endometriosis
title_sort oocyte-secreted serum biomarkers gdf9 and bmp15 in women with endometriosis
topic Reproductive Biology: Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160143/
https://www.ncbi.nlm.nih.gov/pubmed/36380138
http://dx.doi.org/10.1007/s43032-022-01107-6
work_keys_str_mv AT shamsaaiat oocytesecretedserumbiomarkersgdf9andbmp15inwomenwithendometriosis
AT gilchristrobertb oocytesecretedserumbiomarkersgdf9andbmp15inwomenwithendometriosis
AT robertsondavidm oocytesecretedserumbiomarkersgdf9andbmp15inwomenwithendometriosis
AT rodgersrachaelj oocytesecretedserumbiomarkersgdf9andbmp15inwomenwithendometriosis
AT donoghoemarkw oocytesecretedserumbiomarkersgdf9andbmp15inwomenwithendometriosis
AT ledgerwilliaml oocytesecretedserumbiomarkersgdf9andbmp15inwomenwithendometriosis
AT abbottjasona oocytesecretedserumbiomarkersgdf9andbmp15inwomenwithendometriosis
AT riepsamenangeliqueh oocytesecretedserumbiomarkersgdf9andbmp15inwomenwithendometriosis